date:Nov 29, 2012
hodology and design of the paper as it had raised by EFSA. Those were:
Unclear study objectives
Low number of rats used in each treatment group
Lack of detail on the feed and treatment formulation
Key information missing on the statistical methods employed
Incomplete endpoint reporting
Inadequate sample size
Commenting on the EFSAs initial finding, a spokesman for Monsanto said: EFSAs finding clearly rejects the claims made by Seralini et al. They confirm the existing safety assessment by EFSA